Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA

Abstract Background Pompe disease (PD) is an autosomal recessive lysosomal storage disorder caused by the deficient activity of acid alpha glucosidase (GAA) enzyme due to mutations in the GAA gene. As a result, undigested glycogen accumulates within lysosomes causing their dysfunction. From a clinic...

Full description

Saved in:
Bibliographic Details
Main Authors: Paolo Peruzzo, Natascha Bergamin, Martina Bon, Sara Cappelli, Alessandra Longo, Elisa Goina, Cristiana Stuani, Emanuele Buratti, Andrea Dardis
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Molecular Medicine
Subjects:
Online Access:https://doi.org/10.1186/s10020-025-01090-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823862004975140864
author Paolo Peruzzo
Natascha Bergamin
Martina Bon
Sara Cappelli
Alessandra Longo
Elisa Goina
Cristiana Stuani
Emanuele Buratti
Andrea Dardis
author_facet Paolo Peruzzo
Natascha Bergamin
Martina Bon
Sara Cappelli
Alessandra Longo
Elisa Goina
Cristiana Stuani
Emanuele Buratti
Andrea Dardis
author_sort Paolo Peruzzo
collection DOAJ
description Abstract Background Pompe disease (PD) is an autosomal recessive lysosomal storage disorder caused by the deficient activity of acid alpha glucosidase (GAA) enzyme due to mutations in the GAA gene. As a result, undigested glycogen accumulates within lysosomes causing their dysfunction. From a clinical point of view, the disease can be classified in infantile-onset (IO) and late-onset (LO) forms. The common GAA c.-32-13T>G variant, found in 40–70% of LO-PD alleles, is a leaky splicing mutation interfering with the correct GAA exon 2 recognition by the spliceosome leading to the production of non-functional GAA transcripts. In this study, we used modified, GAA-tailored U1 snRNAs to correct the aberrant splicing determined by the c.-32-13T>G and other GAA exon 2-skipping mutations. Methods A set of constructs expressing 5 different engineered U1 snRNAs was generated. A functional splicing assay using a GAA hybrid minigene carrying different variants known to affect GAA exon 2 splicing was used to test the effect of engineered U1 snRNAs on exon 2 inclusion. The effect on endogenously expressed GAA transcript and GAA enzymatic activity was assessed by transfecting patient-derived fibroblasts bearing the common c.-32-13T>G with the best performing modified U1 snRNA. Results Modified U1-3, U1+1 and U1+6 snRNAs were all able to increase, in a dose-dependent manner, the inclusion of exon 2 within the transcript derived from the GAA minigene harbouring the c.-32-13T>G variant. The U1+1 was the most effective one (2,5 fold increase). Moreover, U1+1 snRNA partially rescued the correct splicing of GAA minigenes harbouring mutations that affect the 3’ss (c.-32-3C>G, c.-32-2A>G) and the 5’ss (c.546G>A, c.546G>C, c.546G>T). Notably, the treatment of patient-derived fibroblasts carrying the c.-32-13T>G mutation with the U1+1 snRNA increased the amount of normal GAA mRNA by 1,8 fold and the GAA enzymatic activity by 70%. Conclusions we provide the proof-of-concept for the use of modified GAA-tailored U1 snRNAs, designed to potentiate the recognition of the GAA exon 2 5’ss, as therapeutic tools to correct the aberrant transcripts carrying variants that affect exon 2 splicing, including the common c.-32-13T>G variant.
format Article
id doaj-art-d5f8fbdaf63547a1b867778975a3c17f
institution Kabale University
issn 1528-3658
language English
publishDate 2025-02-01
publisher BMC
record_format Article
series Molecular Medicine
spelling doaj-art-d5f8fbdaf63547a1b867778975a3c17f2025-02-09T12:42:14ZengBMCMolecular Medicine1528-36582025-02-0131111410.1186/s10020-025-01090-zRescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNAPaolo Peruzzo0Natascha Bergamin1Martina Bon2Sara Cappelli3Alessandra Longo4Elisa Goina5Cristiana Stuani6Emanuele Buratti7Andrea Dardis8Regional Coordinator Centre for Rare Diseases, University Hospital of UdineRegional Coordinator Centre for Rare Diseases, University Hospital of UdineRegional Coordinator Centre for Rare Diseases, University Hospital of UdineInternational Centre for Genetic Engineering and Biotechnology (ICGEB)International Centre for Genetic Engineering and Biotechnology (ICGEB)International Centre for Genetic Engineering and Biotechnology (ICGEB)International Centre for Genetic Engineering and Biotechnology (ICGEB)International Centre for Genetic Engineering and Biotechnology (ICGEB)Regional Coordinator Centre for Rare Diseases, University Hospital of UdineAbstract Background Pompe disease (PD) is an autosomal recessive lysosomal storage disorder caused by the deficient activity of acid alpha glucosidase (GAA) enzyme due to mutations in the GAA gene. As a result, undigested glycogen accumulates within lysosomes causing their dysfunction. From a clinical point of view, the disease can be classified in infantile-onset (IO) and late-onset (LO) forms. The common GAA c.-32-13T>G variant, found in 40–70% of LO-PD alleles, is a leaky splicing mutation interfering with the correct GAA exon 2 recognition by the spliceosome leading to the production of non-functional GAA transcripts. In this study, we used modified, GAA-tailored U1 snRNAs to correct the aberrant splicing determined by the c.-32-13T>G and other GAA exon 2-skipping mutations. Methods A set of constructs expressing 5 different engineered U1 snRNAs was generated. A functional splicing assay using a GAA hybrid minigene carrying different variants known to affect GAA exon 2 splicing was used to test the effect of engineered U1 snRNAs on exon 2 inclusion. The effect on endogenously expressed GAA transcript and GAA enzymatic activity was assessed by transfecting patient-derived fibroblasts bearing the common c.-32-13T>G with the best performing modified U1 snRNA. Results Modified U1-3, U1+1 and U1+6 snRNAs were all able to increase, in a dose-dependent manner, the inclusion of exon 2 within the transcript derived from the GAA minigene harbouring the c.-32-13T>G variant. The U1+1 was the most effective one (2,5 fold increase). Moreover, U1+1 snRNA partially rescued the correct splicing of GAA minigenes harbouring mutations that affect the 3’ss (c.-32-3C>G, c.-32-2A>G) and the 5’ss (c.546G>A, c.546G>C, c.546G>T). Notably, the treatment of patient-derived fibroblasts carrying the c.-32-13T>G mutation with the U1+1 snRNA increased the amount of normal GAA mRNA by 1,8 fold and the GAA enzymatic activity by 70%. Conclusions we provide the proof-of-concept for the use of modified GAA-tailored U1 snRNAs, designed to potentiate the recognition of the GAA exon 2 5’ss, as therapeutic tools to correct the aberrant transcripts carrying variants that affect exon 2 splicing, including the common c.-32-13T>G variant.https://doi.org/10.1186/s10020-025-01090-zPompe diseaseGlycogenosis type IIGAASplicingU1c.-32-13T>G
spellingShingle Paolo Peruzzo
Natascha Bergamin
Martina Bon
Sara Cappelli
Alessandra Longo
Elisa Goina
Cristiana Stuani
Emanuele Buratti
Andrea Dardis
Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA
Molecular Medicine
Pompe disease
Glycogenosis type II
GAA
Splicing
U1
c.-32-13T>G
title Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA
title_full Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA
title_fullStr Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA
title_full_unstemmed Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA
title_short Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA
title_sort rescue of common and rare exon 2 skipping variants of the gaa gene using modified u1 snrna
topic Pompe disease
Glycogenosis type II
GAA
Splicing
U1
c.-32-13T>G
url https://doi.org/10.1186/s10020-025-01090-z
work_keys_str_mv AT paoloperuzzo rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna
AT nataschabergamin rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna
AT martinabon rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna
AT saracappelli rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna
AT alessandralongo rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna
AT elisagoina rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna
AT cristianastuani rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna
AT emanueleburatti rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna
AT andreadardis rescueofcommonandrareexon2skippingvariantsofthegaageneusingmodifiedu1snrna